Intended for licensed healthcare professionals located in the Republic of Ireland only.
Because Tomorrows Matters Today

Together, we've treated over 15,000 patients with ICLUSIG, building experience and confidence in patients' futures1,2

Blue square
Have you considered all types of patients with CP-CML who are eligible and may benefit from treatment with ICLUSIG?
Representative patient cases – not actual patients

Highly resistant with no mutations or history of CV events

Resistant to 1L imatinib and 2L dasatinib

Personal information

  • Age: 69 years
  • Sex: Female

Clinical background

  • CP-CML diagnosis: 36 months ago
  • Treatment history: 1L imatinib for 24 months (resistant), 2L dasatinib until 36 months (resistant)
  • BCR::ABL1IS level: 8%
  • Mutation status: No known mutation
  • ELTS score: Low
  • CV risk factors: No history of CV events

Treatment history

Graph

The most frequent mechanisms of resistance in CP-CML are BCR::ABL1-independent3

ELN CML Guidelines (2020) recommend that patients who are resistant to a 2G TKI with no mutation detected should be treated with ICLUSIG instead of another 2G TKI, unless CV risk factors preclude its use4

Highly resistant with no history of CV events

Resistant to 1L dasatinib; T315I+

Personal information

  • Age: 55 years
  • Sex: Male

Clinical background

  • CP-CML diagnosis: 60 months ago
  • Previous treatments: 1L dasatinib for 60 months (resistant)
  • Mutation status: T315I+ (detected at 56 months)
  • BCR::ABL1IS level: 4%
  • ELTS score: Low
  • CV risk factors: Former smoker, but no history of CV events

Treatment history

Graph

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all single BCR::ABL1 resistance mutations, including T315I1,5–7

ELN CML Guidelines (2020) note that ICLUSIG is the only TKI with activity against the T315I mutant, and recommend ICLUSIG in patients with T315I, unless CV risk factors preclude its use4

Highly resistant with well-controlled dyslipidaemia

Resistant to 1L dasatinib; V299L+

Personal information

  • Age: 72 years
  • Sex: Female

Clinical background

  • CP-CML diagnosis: 48 months ago
  • Previous treatments: 1L dasatinib for 48 months (resistant)
  • Mutation status: V299L+ (detected at 48 months)
  • BCR::ABL1IS level: 2.8%
  • ELTS score: Intermediate
  • CV risk factors: Family history of dyslipidaemia - prescribed statins to balance lipid levels after lifestyle changes were ineffective

Treatment history

Graph

ICLUSIG, a 3G TKI, is the only UK-approved BCR::ABL1 inhibitor designed to be effective in CML patients with or without resistance mutations, including V299L4,8,9

ELN CML Guidelines (2020) recommend that patients who are resistant to a 2G TKI should be treated with ICLUSIG instead of another 2G TKI, unless CV risk factors preclude its use4

Resistant with no history of CV events

Resistant to 1L nilotinib; E255K+

Personal information

  • Age: 47 years
  • Sex: Male

Clinical background

  • CP-CML diagnosis: 60 months ago
  • Treatment history: 1L nilotinib for 60 months (resistant)
  • Mutation status: E255K+ (detected at 56 months)
  • BCR::ABL1IS level: 2%
  • ELTS score: Low
  • CV risk factors: No history of CV events

Treatment history

Graph

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all single BCR::ABL1 resistance mutations, including E255K1,6,7

ELN CML Guidelines (2020) recommend that patients who are resistant to a 2G TKI should be treated with ICLUSIG instead of another 2G TKI, unless CV risk factors preclude its use4

Resistant with well-controlled hypertension and hypercholesterolaemia

Resistant to 1L imatinib and 2L dasatinib; F317L+

Hypertension may contribute to the risk of arterial occlusive events. ICLUSIG treatment should be temporarily interrupted if hypertension is not medically controlled.

Personal information

  • Age: 65 years
  • Sex: Female

Clinical background

  • CP-CML diagnosis: 42 months ago
  • Treatment history: 1L imatinib for 24 months (resistant), 2L dasatinib until 42 months (resistant)
  • Mutation status: F317L+ (detected at 42 months)
  • BCR::ABL1IS level: 1.2%
  • ELTS score: Intermediate
  • CV risk factors: well-controlled hypertension and hypercholesterolaemia

Treatment history

Graph

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all single BCR::ABL1 resistance mutations, including F317L1,6,7

ELN CML Guidelines (2020) recommend that patients who are resistant to a 2G TKI should be treated with ICLUSIG instead of another 2G TKI, unless CV risk factors preclude its use4
Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number 1800-456-748.